
==== Front
Drug Deliv Transl Res
Drug Deliv Transl Res
Drug Delivery and Translational Research
2190-393X
2190-3948
Springer US New York

38478324
1556
10.1007/s13346-024-01556-3
Original Article
OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline
http://orcid.org/0000-0001-6945-6653
d’Avanzo Nicola 1
http://orcid.org/0000-0002-5223-9879
Paolino Donatella 1
http://orcid.org/0000-0002-8160-8610
Barone Antonella 1
http://orcid.org/0000-0001-5124-1750
Ciriolo Luigi 2
http://orcid.org/0000-0002-0915-8643
Mancuso Antonia 1
http://orcid.org/0000-0002-5510-7599
Christiano Maria Chiara 3
http://orcid.org/0000-0001-5077-0845
Tolomeo Anna Maria 45
http://orcid.org/0000-0002-0590-5429
Celia Christian c.celia@unich.it

678
http://orcid.org/0000-0001-6967-7050
Deng Xiaoyong xydeng@shu.edu.cn

8
http://orcid.org/0000-0001-8062-817X
Fresta Massimo fresta@unicz.it

2
1 grid.411489.1 0000 0001 2168 2547 Department of Clinical and Experimental Medicine, University of Catanzaro “Magna Graecia”, Viale “S. Venuta”, 88100 Catanzaro, Italy
2 grid.411489.1 0000 0001 2168 2547 Department of Health Sciences, University of Catanzaro “Magna Graecia”, Viale “S. Venuta”, 88100 Catanzaro, Italy
3 grid.411489.1 0000 0001 2168 2547 Department of Medical and Surgical Sciences, University of Catanzaro “Magna Graecia”, Viale “S. Venuta”, 88100 Catanzaro, Italy
4 https://ror.org/00240q980 grid.5608.b 0000 0004 1757 3470 Department of Cardiac, Thoracic and Vascular Science and Public Health, University of Padova, 35128 Padua, Italy
5 Perdiatric Research Institute “Città della Speranza”, Corso Stati Uniti, 4, 35127 Padua, Italy
6 https://ror.org/00qjgza05 grid.412451.7 0000 0001 2181 4941 Department of Pharmacy, University of Chieti – Pescara “G. d’Annunzio”, Via dei Vestini 31, 66100 Chieti, Italy
7 https://ror.org/0069bkg23 grid.45083.3a 0000 0004 0432 6841 Lithuanian University of Health Sciences, Laboratory of Drug Targets Histopathology, Institute of Cardiology, A. Mickeviciaus g. 9, LT-44307 Kaunas, Lithuania
8 https://ror.org/006teas31 grid.39436.3b 0000 0001 2323 5732 Institute of Nanochemistry and Nanobiology, School of Environmental and Chemical Engineering, Shanghai University, Shanghai, 200444 China
13 3 2024
13 3 2024
2024
14 10 27712787
19 2 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Cerebrovascular impairment represents one of the main causes of death worldwide with a mortality rate of 5.5 million per year. The disability of 50% of surviving patients has high social impacts and costs in long period treatment for national healthcare systems. For these reasons, the efficacious clinical treatment of patients, with brain ischemic stroke, remains a medical need. To this aim, a liposome nanomedicine, with monosialic ganglioside type 1 (GM1), OX26 (an anti-transferrin receptor antibody), and CDP-choline (a neurotrophic drug) (CDP-choline/OX26Lip) was prepared. CDP-choline/OX26Lip were prepared by a freeze and thaw method and then extruded through polycarbonate filters, to have narrow size distributed liposomes of ~80 nm. CDP-choline/OX26Lip were stable in human serum, they had suitable pharmacokinetic properties, and 30.0 ± 4.2% of the injected drug was still present in the blood stream 12 h after its systemic injection. The post-ischemic therapeutic effect of CDP-choline/OX26Lip is higher than CDP-choline/Lip, thus showing a significantly high survival rate of the re-perfused post-ischemic rats, i.e. 96% and 78% after 8 days. The treatment with CDP-choline/OX26Lip significantly decreased the peroxidation rate of ~5-times compared to CDP-choline/Lip; and the resulting conjugated dienes, that was 13.9 ± 1.1 mmol/mg proteins for CDP-choline/Lip and 3.1 ± 0.8 for CDP-choline/OX26Lip. OX26 increased the accumulation of GM1-liposomes in the brain tissues and thus the efficacious of CDP-choline. Therefore, this nanomedicine may represent a strategy for the reassessment of CDP-choline to treat post-ischemic events caused by brain stroke, and respond to a significant clinical need.

Graphical abstract

Supplementary Information

The online version contains supplementary material available at 10.1007/s13346-024-01556-3.

Keywords

Liposomes
Brain targeting
Nanomedicine
CDP-choline
Stroke
Università degli studi "Magna Graecia" di CatanzaroOpen access funding provided by Università degli studi "Magna Graecia" di Catanzaro within the CRUI-CARE Agreement.

issue-copyright-statement© Controlled Release Society 2024
==== Body
pmcIntroduction

Cerebrovascular stroke is currently one of the major causes of death worldwide, with a mortality rate of 5.5 million per year or long-term adult disability in 50% of survived patients [1, 2], as well as high comorbidity healthcare costs [3–5].

Clinical studies and case reports showed an increasing incidence of cerebral stroke because of several risk factors [2], as well as the socioeconomic improvement, business development, and environmental pollutants [6]. All these components increase hypertension and hypercholesterolemia, diabetes, and obesity in persons that had a fatty diet [6].

Stroke is a complex disease which includes ischemic and hemorrhagic events, caused by the partial or total obstruction of blood vessels and a significant reduction of the oxygen flux and glucose uptake in specific brain’s areas, or the bleeding in the brain tissue, with the following collapse of capillary vessels [7, 8].

To date, ischemic stroke is the most prevalent form of stroke worldwide and it is characterized by a primary damage in the brain ischemic core and a rapid secondary damage in the neighbor areas, or penumbra zone [2, 9]. The extent of neuronal damage is strongly affected by timing occurred between ischemia and reperfusion process [10]. The delay in the primary restoring procedure of ischemic stroke leads to the impairment of the different surrounding brain tissues’ function, thus eliciting a significant modifications of biochemical and metabolic pathways, with the final result of a post-ischemic neurodegeneration [11]. Although no therapeutic strategies are currently available to reduce damages in the ischemic core, different therapies are used to treat post-ischemic maturation process and to reduce injuries associated with brain neighboring area [12].

In this scenario, the brain supplements play a crucial role for restoring the damaged-no-death neurons and in particular, CDP-choline was a blockbuster drug which has been widely used to reduce the stroke-associated injuries [13, 14]. Despite clinical randomized trial in 2012 showed no significant therapeutic activity of CDP-choline in patients following ischemic stroke [15, 16], several preclinical studies in ischemic animal models were carried out, and demonstrated that the lack of CDP-choline effectiveness was due to its poor pharmacokinetic and physicochemical properties, which strongly limit the CDP-choline transport across the blood brain barrier (BBB) [17].

Nanotechnology, and the use of drug delivery systems, may overcome these drawbacks and improves both the targeting of injured tissues as well as the biopharmaceutical properties of CDP-choline after systemic administration. Liposomes significantly improved the therapeutic effect of CDP-choline in ischemic rats [18–21]. This improvement and the relative safety profile of CDP-choline delivery strongly supported the hypothesis of lipid-based nanomedicines for future clinical trials [17].

The brain targeting nanomedicines provided several options to increase the uptake and accumulation of payloads in different brain areas and had a selective efficaciousness with decreased systemic side effects [22, 23]. Biomarkers and mediator receptors, overexpressed in the brain capillary endothelial cells of BBB and involved in basal and metabolic brain physiological functions, provide a huge platform for brain targeting of nanomedicines after local or systemic injections [24].

The anti-transferrin receptor antibody conjugated to liposomes increased intracellular uptake and tissues targeting [25–27]. Recently, the gangliosides have been reconsidered as potential neuroprotective agents to treat brain degenerative diseases [28, 29]. The great interest of the scientific community is further demonstrated by the clinical trial (phase I) of Talineuren, a monosialic ganglioside type 1 (GM1)-based liposomes for the treatment of Parkinson disease. Moreover, monosialic gangliosides decreased the potential immunogenicity of polymers, like PEG that are used for the long-circulation of nanocarriers after systemic injection [30], and may represent a valid option for the development of nanomedicine-based therapies for brain disorders.

The aim of this work is the preparation of CDP-choline-loaded GM1-liposomes conjugated with anti-transferrin receptor antibody (OX26) for brain targeting delivery of this drug, and the improve of CDP-choline therapeutic effect in the brain ischemic stroke. OX26-conjugated CDP-choline-loaded GM1-liposomes were prepared, physicochemical characterized and tested in vivo on ischemic stroke rat models. Results demonstrated that OX26-bearing liposomes have suitable pharmacokinetic and biopharmaceutical properties for in vivo administration and increase the survival rate of ischemic and reperfusion rats.

Materials and methods

Materials

Cholesterol (CHOL), Sephadex G-25, phosphate buffered saline (PBS) solution and CDP-choline sodium salt hydrate were obtained from Merck (Milan, Italy). 1,2- dipalmitoyl-sn-glycero-3-phospocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine (DPPS); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] (DSPE-PEG2000mal), N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3 phosphoethanolamine (DSPE-mPEG2k) and Monosialo Ganglioside (GM1) were purchased from Avanti Polar (Merck, Milan, Italy). [3H]-cholesteryl hexadecyl ether ([3H]CHE, 40 Ci/mmol) was purchased from Perkin Elmer-Italia (Monza, Italy). Mouse monoclonal transferrin receptor antibody (OX26) was obtained from BD Biosciences (Milan, Italy).

All the other reagents, that used during the experiments, were of analytical grade and are used without any further purification. Wistar rats were obtained from Harlam (Italy s.r.l. San Pietro al Natisone (UD), Italy).

Methods

Liposome preparation

Liposomes were prepared by using thin layer evaporation method with some modifications as previously reported [19, 31]. Briefly, DPPC, DPPS, Chol, GM1 and DSPEmPEG2000-mal, final molar ratio of 3:3:3:0.8:0.2, were co-dissolved by using an organic solvent mixture (chloroform: methanol, 3:1 v/v) in a round glass vial. The organic solvent was removed by using a rotavapor Büchi R-210 at 45 °C (Büchi, Milan, Italy) connected to a vacuum pump. The thin lipid film was hydrated with an aqueous solution of 40 mg/mL of CDP-choline (PBS 10 mM, pH 6.8), and a final lipid concentration of 50 mg/mL was obtained. Three minutes of warming at 60 °C and three minutes of vigorous stirring at 800 rpm were carried out for three times. The resulting multilamellar liposomes were warmed at 60 °C for 1 h and then frozen and thawed (5 min in liquid nitrogen and 15 min at 60 °C) ten-folds to improve the entrapment efficiency of the payload. The liposomal suspension was then extruded through polycarbonate filters with a pore size from 800 to 50 nm (Whatman® Nuclepore™ Track-Etched Membranes, Merk Life Science S.r.l., Milan, Italy), by using a stainless-steel extrusion device (Lipex Biomembranes, Northern Lipids Inc., Vancouver, BC, Canada). The un-entrapped drug was removed by using Amicon® Ultra centrifugal filters (cut-off 50 kDa).

The OX26 antibody was finally conjugated to the surface of small unilamellar liposomes as following reported.

Untargeted CDP-choline-loaded liposomes (CDP-choline/Lip) were prepared by replacing DSPEmPEG2000-mal with the same molar ratio of DSPEmPEG2000 during the lipid film preparation, while empty liposomes were made up by hydrating lipid film with PBS (pH 7.4, 10 mM). Radiolabeled liposomes were prepared by using [3H]-cholesteryl hexadecyl ether ([3H]CHE, 0.003% w/w) at a final concentration of 0.5 µCi/mL.

Antibody conjugation

A sulfhydryl group was added to the N-terminal portion of OX26 antibody by using SATA reagent as previously reported elsewhere with some modifications [32]. A stock solution of SATA was prepared by dissolving this compound (6 mg) in 1 mL of DMF. 1 μL of resulting solution was added to 1 mL of OX26 solution (0.5 mg/mL in PBS at pH 7.4) to have a final molar ratio between SATA and antibody of at least 8:1. The resulting mixture was incubated for 30 min at room temperature and then purified by using amicon ultracentrifuge tube (cut-off 3 kDa, Merck Millipore S.A.S., France). The acetylated OX26 was stored at -80 °C upon their use, de-acetylated by incubation with de-acetylating solution (0.5 M hydroxylamine.HCl, 25 mM EDTA in PBS, pH 7.4) at room temperature for 2 h, and then conjugated to liposomes (Fig. 1). The thiolate antibody was purified with desalting columns pre-equilibrated with PBS buffer (PBS 10 mM, 10 mM EDTA, pH 6.8) and concentrated up to 1 mL by using amicon ultracentrifuge tube. The presence of thiol group on modified OX26 was carried out by the Ellman reaction (data not shown) as previously published [33].Fig. 1 Schematic representation of OX26 conjugation on liposome surface. The conjugation of OX26 to liposomes was obtained between thiol group of OX26 and maleimide group of DSPE-PEG2000-mal

Thiolate OX26 antibody (800 μL, 0.5 mg/mL) was conjugated to the surface of liposomes (lipid concentration 50 mg/mL) through the reaction between thiol group in the backbone of antibody and maleimide residual of DSPEmPEG2000-mal on the surface of liposomes by incubation at room temperature for 3 h, followed by an overnight incubation at 4 °C under continuous magnetic stirring (250 rpm) (Fig. 1). Ethanethiol was used at the end of reaction to block un-reacted maleimide residuals. The resulting OX26 liposomes were purified with exclusion chromatography by using the Akta Prime apparatus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) with a glass column packed with Sephadex G-25 and equipped with a spectrophotometer at fixed wavelength of 280 nm. When required, after purification, liposomes were concentrated by using total recovery amicon ultracentrifuge tube with a pore size of 50 kDa (Merck Millipore S.A.S., France).

Physicochemical characterization

The average size, size distribution and zeta potential of liposomes were analyzed by using dynamic light scattering (DLS) technique as previously reported with some modifications [34]. Briefly, samples were diluted with isosmotic pyrogen free solution (1:50 v/v) to avoid multiscattering phenomena, and the analysis was carried out at 25 °C by using Zetasizer Nano ZS (Malvern Panalytical Ltd, UK). Results are the average of three independent analyses ± standard deviation (S.D.). The conjugated OX26 was indirectly quantified as previously reported with some modifications [35]. OX26-conjugated liposomes were centrifuged at 90,000 × g (1 h, 4 °C) and the concentration of OX26 in the supernatant was quantified by Mouse IgG2a ELISA quantification kit (Sigma Aldrich, Milan, Italy). The amount of OX26 conjugated on the liposome surface was then calculated by deleting the amount of unconjugated monoclonal antibody in the supernatant from total amount of OX26 that are used during the liposome preparation.

The morphology of nanovesicles was also studied by using TEM analysis, as previously published [36]. Samples were properly diluted in isosmotic buffer and dropped into coated grids. Uranyl acetate solution (2% w/v) was used to stain the samples after drying. TEM images were acquired by using a Veleta (Olympus Soft Imaging System) digital camera, operating at 100 kV with Tecnai G2 (FEI) transmission electron microscope (TEM).

Drug entrapment efficiency and release kinetic of liposomes

The purified CDP-choline-loaded liposomes were dried under vacuum by using a ThermoScientific™ Savant™ SpeedVac™ (Fisher Scientific Italia, Rodano (MI), Italy) for 12 h. Dried liposomes were dissolved by using cooled methanol (+4 °C) and the CDP-choline entrapment efficiency was evaluated by using HPLC apparatus as previously reported by Lin et al. with some modification [37]. Samples were analyzed by using a C18 column (4.6 × 100 mm, 3 μm, Gemini-Nx plus C18; Phenomenex, CA, USA) at 25 °C. The mobile phase was methanol and KH2PO4 0.5 M (10:90 v/v ratio, respectively) with a flow rate of 1 mL/min. CDP-choline detection was carried out by using a UV-detector connected to HPLC apparatus at 280 nm. Empty liposomes were used as blank and an external calibration curve of CDP-choline, in the range from 1 to 25 μg/mL, was used to quantify the drug inside liposomes. The drug loading percentage (D.L.%) (Eq. 1) and the entrapment efficiency percentage (E.E.%) (Eq. 2) were calculated by using the following equations:1 D.L.%=DenLiptot∗100

2 E.E.%=DenDtot∗100

where, Den is the amount of drug loaded inside liposomes, while Liptot and Dtot are the total amount of lipid, and the total amount of drug that are used during the preparation procedure of liposomes.

The CDP-choline release from liposome was studied in vitro by using the bag dialysis method as previously published with some modification [38]. Briefly, liposomes were filled inside a cellulose acetate dialysis tube (Spectra/Por 1 Standard RC Dry Dialysis Tubing, 50 kDa, Spectrum Labs, USA) and hold in the receptor medium to have a final ratio between liposomes and receptor medium of 1:100 v/v. The release study was carried out at 37 ± 0.5 °C under a slow and continuous stirring (200 rpm) up to 24 h. At fixed time points (30 min, 1, 2, 3, 4, 6, 8, 10, 24 h), 1 mL of receptor medium was withdrawn and replaced with the same volume of fresh medium. Two different media, i.e. PBS (10 mM, pH 7.4) and PBS supplemented with 50% of human plasma, were used to study the kinetic release profile of CDP-choline. To avoid potential interference during the analysis, proteins of human plasma were removed. Briefly, a slight acid methanol solution was mixed with different samples (methanol/sample 3:1 v/v ratio), centrifuged at 11,000 × g for 10 min and the supernatant was then analyzed.

The percentage of CDP-choline released from liposomes was quantify by using the following equation (Eq. 3):3 Drugreleased%=DrelDen∗d.f.×100

where, Drel is the amount of drug released at specific time point, Den is the amount of drug loaded inside liposomes and d.f. is the dilution factor between the volume of liposomes loaded in the dialysis tube and the volume of receptor medium. Any further dilutions, before the analysis, were considered to calculate the amount of CDP-choline released from liposomes. Empty liposomes were used as negative control.

Stability in human plasma

The physical stability of liposomes was tested in a human plasma/PBS mixture (50:50 v/v ratio) (HP/PBS) as previously published with some modifications [39]. Briefly, 400 µL of CDP-choline-loaded OX26-conjugated liposomes (CDP-choline/OX26Lip) were incubated with 2 mL of HP/PBS medium (50% v/v) at 37 °C and then gently stirred up to 24 h. At fixed time points, 100 µL of the resulting mixture were analyzed by using DLS, and the average sizes of liposomes incubated with HP/PBS medium were measured. Liposomes incubated at the same conditions with saline solution (NaCl 0.9% w/v) were used as negative control during the experiment.

Turbiscan lab expert analysis

Turbiscan Lab expert (Formulaction, L’Union, France) was used to test the long-term stability of liposomes at 37 and 25 °C as previously published [40]. Briefly, CDP-choline/Lip (control) and CDP-choline/OX26Lip were hold in a glass vial tube and diluted ten-times with PBS (10 mM, pH 7.4) up to a final volume of 6 mL. The analysis was carried out for the full height of samples (~ 10 mm) for 1 h. A pulsed infrared LED (wavelength of 880 nm) was used for different measurements and the results were reported as transmitted and backscattered lights through and by liposomes. Backscattering and transmittance were measured with optical detectors at 45° and 180°, for evaluating the long-term stability of liposomes. Potential sedimentation, creaming and/or flocculation of colloidal nanoparticles, like liposomes, did not occur with an instrument threshold below or equivalent to 5%. The results were reported for sample height ranging between 2.5 and 10 mm, because variations of backscattering and transmittance profiles over 5% at the sample height of 2 mm and/or over 10 mm are related to the presence of bubbles air at the bottom and top of glass holder, and they are not related to the occurrence of destabilization phenomena [40]. The global destabilization profiles (TSI) of liposomes were also recorded as a function of time up to 1 h of incubation. Moreover, the mean diameter of liposomes was also evaluated during the study and the potential variations have been reported as a function of time.

Animals

Animal studies were carried in accordance with the Guide for the Care and Use of Laboratory Animals from directive 2010/63/EU of the European Parliament and protocols approved by the National Directorate of Veterinary Services (Italy, Permit No. 235 on June 30, 2011). Adult Wistar rats (250–300 g, body weight) were used for these studies and housed at 25 °C, 65% relative humidity, 12 h dark/12 h light cycle, with water and food ad libitum.

Biodistribution studies

Long-circulating properties of CDP-choline/OX26Lip and the relative uptake in the main RES organs (i.e. liver and spleen) were studied by injecting [3H]-labeled liposomes in the tail vain of rat (average weight of ~ 270 g). At fixed time points after injection (3, 12 and 24 h) the animals were sacrificed, and the tissues were collected for the analysis. Three animals were used at different time points for each independent experiment, and three independent experiments were carried out. Briefly, organs were hold into polypropylene-based liquid scintillation cylinder vials (Sigma-Aldrich Chemie, GmbH, Steinheim, Germany) and incubated (4 h at 60 °C under continuous stirring) with 2 mL of quaternary ammonium hydroxide solution (Sigma-Aldrich Chemie, GmbH, Steinheim, Germany) to have a complete dissolution of tissues. Hydrogen peroxide (2 mL at 24% v/v) was used to decolorize the mixture and 7 mL of liquid scintillation cocktail (Ready Organic™, Beckman Coulter Inc., Fullerton, USA) was further added to samples and vigorously mixed. The resulting samples were quantified by using Wallac Win Spectral™ 1414 liquid scintillation counter coulter (PerkinElmer Life and Analytical Sciences, Inc. Waltham, MA, USA) and data were analyzed by 1414 Win Spectral Wallac LCS Software. The quantification of radio-labeled liposomes accumulated in different tissues was performed as previously published [41]. The signal intensity of endothelium and blood, which interfered with collected samples, was corrected and the following equation (Eq. 4) was used for the analysis:4 Rtissue=Rorgan-V0∗Ct

where, Rtissue is the corrected radioactivity, Rorgan is the level of radioactivity measured in the different samples, V0 is the total volume of interstitial fluid and vasculature calculated as a ratio between the whole organ radioactivity levels and the blood concentration 1 min after the injection of radio-labeled liposomes, and Ct is the blood concentration at time t. The radioactive intensity of organs collected from control (untreated rats) was used as a further correction factor.

Induction of ischemic stroke in rats

The ischemic stroke in adult male Wistar rats (250–300 g) was induced according to experimental protocol previously reported with some modification [19]. Briefly, the animals were anesthetized [42] by isoflurane inhalation (2.5% in 100% oxygen) and then the ischemic stroke was induced by the bilateral occlusion of the common carotid arteries. 30 min after occlusion, the blood flow was restored, and the ischemic animals were split in different groups and injected with different formulations for the evaluation of the therapeutic activity.

In vivo therapeutic activity

Therapeutic efficacy of CDP-choline/OX26Lip was carried out by injecting liposomes in Wistar rats, during the reperfusion process and once a day for six days. The survival rate of treated animals was studied up to 8 days after the induction of ischemic event. The survival rate percentage (%) was calculated according to the following equation (Eq. 5):5 Survivalrate%=survivedanimalstotalanimaltreated∗100

Liposomes were intravenously injected into the tail vein at a CDP-choline dose of 20 mg/kg. CDP-choline/Lip were injected at the same drug dose. Saline solution was used as a control. For each group a total number of 15 animals were used (5 animals in each group for every independent experiment, with a total number of 3 independent experiments).

For the study of lipid peroxidation and lactate levels, 1 h after reperfusion, the animals were sacrificed and then the analysis was carried out as previously published [19].

Statistical analysis

The statistical significance was carried out by One-way analysis of variance (ANOVA) and Tukey’s multiple comparison test. Analysis was performed by using SigmaPlot v.12 and Excel (Office 2010) and the significance levels was carried out for *p < 0.05, **p < 0.01 and ***p < 0.001.

Results and discussion

Physicochemical characterization

The optimization of physicochemical properties in drug delivery systems, such as particle size, size distribution, shape and interface properties, is one of the main challenge during the design of a potential nanomedicine, and it affects the biodistribution and metabolism of payloads as well as nanocarriers following the systemic injections [43]. Drug delivery systems can be further optimized for targeting tissue and physiological/pathological components. In these attempts, monosialic ganglioside (GM1) was used to make CDP-choline liposomes for two reasons: i) the intrinsic neuroprotective and antioxidant properties of GM1 [28, 29, 44, 45], that further increases the neurotrophic activity of CDP-choline; ii) the stealth properties of GM1 that has similar long-circulating properties of polyethylene glycol (PEG) but does not activate the anti-PEG immunogenic reactions [30].

The physicochemical characterization of CDP-choline/OX26Lip showed a mean size almost twice (84 ± 5 vs 54 ± 2, Table 1) compared to the untargeted CDP-choline/Lip, which has a lipid composition similar to those previously published by our research group [19]. The increase of nanoparticle size depended on the conjugation of OX26 on the liposomal surface. In fact, the hydrophilic property of the antibody increases the hydrodynamic diameter of liposome [46]. Table 1 Physicochemical properties

Sample	Average diameter
(nm)	Zeta-potential
(mV)	PDI	
CDP-choline/Lip	54 ± 2	-36.6 ± 2.9	0.04 ± 0.01	
CDP-choline/OX26Lip	84 ± 5***	-29.0 ± 2.3*	0.06 ± 0.03	
The average diameter (nm), Z-potential and particle size distribution (PDI) were measured by using Zetasizer Nano ZS. Results are the average of three independent experiments ± standard deviation (S.D.)

Statistical significance *p < 0.05; **p < 0.01; ***p < 0.001

The conjugation of the OX26 antibody (final concentration 7.5 μg/μmol) further modified the Z-potential of liposomes from -36.6 ± 2.9 to -29.0 ± 2.3 (Table 1). In fact, the positively charged amino acids, present in the OX26 backbone, decreased the net negative surface charge of liposomes made up from DPPS and GM1 [31]. Conversely, the PDI values were below 0.1 and there were not any significant difference between CDP-choline/Lip and CDP-choline/OX26Lip (Table 1), thus showing a narrow size distribution of liposomes [47].

DLS data agreed with TEM analysis (Fig. 2) and showed that liposomes had small unilamellar structures and a quite homogeneous size distribution. The TEM images showed that resulting liposomes had a round-shape morphology.Fig. 2 Schematic representation of transmission electron microscopy (left side) and representative images (right side). Panels A and B show CDP-choline/Lip and CDP-choline/OX26Lip. Scale bar: 100 nm. Images are representative of three independent analyses

These data demonstrated that CDP-choline/OX26Lip have suitable physicochemical properties for in vivo administration and brain targeting, i.e. an average diameter below 100 nm [48], a net negative Z-potential value with suitable electrostatic repulsion between vesicles in suspension [49, 50], a narrow size distribution [51] and the presence of OX26 targeting molecules on the liposomal surface [35]. Namely, the conjugation of OX26 to liposomes, as well as their average sizes below the cut-off of brain vasculature fenestration during ischemic process, favors the liposome targeting into the brain after in vivo administration [18, 52].

Entrapment efficiency and release kinetic of liposomes

CDP-choline is loaded in the aqueous core of liposomes and size exclusion chromatography/ultrafiltration has been used to remove the un-entrapped drug and un-conjugated OX26, as reported elsewhere [53]. The presence of OX26 antibody on the surface of liposomes did not affect neither the loading efficiency nor the entrapment efficiency, 32.3 ± 3.5% and 40.4 ± 2.0% vs 30.1 ± 1.7% and 37.5 ± 1.8%, for CDP-choline/Lip and CDP-choline/OX26Lip, respectively (Fig. 3). Results agreed with data previously published by our research group, which had similar loading efficiency for CDP-choline in untargeted liposomes with similar lipid compositions [54].Fig. 3 CDP-choline entrapment efficiency percentage, loading degree percentage and release kinetic profiles of liposomes. CDP-choline (drug) loading and entrapment efficiency percentage for conjugated (CDP-choline/OX26Lip) and unconjugated (CDP-choline/Lip) liposomes are reported in the panel A. The release kinetic of CDP-choline from liposomes was tested in vitro in PBS (panel B) and PBS supplemented with human plasma (PBS-HP) (50% v/v) (panel C), to simulate in vivo conditions after systemic injection. Results are the average of three independent experiments ± standard deviation (S.D.)

CDP-choline/Lip and CDP-choline/OX26Lip showed a biphasic release profile with a rapid release of ~20% of CDP-choline during the first 2 h of incubation, followed by a pseudo-steady state up to 24 h if PBS was used as a receptor medium (Fig. 3B). Results obtained for the release kinetic profile of CDP-choline/Lip agreed data previously published by our research group [55], that studies liposomes with a similar lipid composition, and endorse that the presence of DSPEmPEG2000 at 2% molar ratio in the lipid bilayer did not modify the release of CDP-choline from liposomes. The rapid release of ~20% of CDP-choline may depend on the leakage of drug adsorbed on the external bilayer that makes hydrogen bonds with DPPS [18]. In fact, the larger volume of buffer in the receptor medium, than that loaded in the dialysis bag, generated a constant osmotic gradient that caused the leakage of ~20% CDP-choline.

Similar results were obtained for the release studies that have carried out in PBS-HP (50% v/v) up to 10 h of incubation (Fig. 3C). Conversely, a significant increase of drug release (15% higher than that obtained in PBS buffer) was obtained for both CDP-choline/Lip and CDP-choline/OX26Lip when the experiments were carried out in PBS-HP after 24 h of incubation (Fig. 3B, C). This difference may depend on the human plasma proteins dispersed in the receptor medium, which increase the osmotic pressure in the receptor medium and make some complexes with the released CDP-choline thus leading to an overall increased release of drug after 24 h of incubation. Moreover, the low molecular weight proteins, as well as the proteolytic fragment in the human plasma, can pass through the pores of polycarbonate dialysis tube, are adsorb on the surface of liposomes and modify the supramolecular structure and the interface properties of liposomes after 24 h of incubation. While, the ganglioside and PEG coated liposomes made a steric barrier on the liposomal surface that hampered the interaction between nanovesicles and human circulating proteins at early incubation times [56], thus resulting in a release kinetic profile that was similar to that obtained in PBS up to 10 h of incubation (Fig. 3B, C). The results showed that there is no significant variation of CDP-choline release between CDP-choline/Lip and CDP-choline/OX26Lip, thus highlighting that the antibody conjugation onto the nanovesicle surface did not affect the release of drug.

Stability study of liposomes in human plasma

The interaction of nanomedicines with biological fluids can affect their stability, metabolism, biodistribution, targeting, and efficacy after systemic administration [57]. The circulating proteins, like albumin, can be adsorbed on the surface of liposomes, thus making protein corona that causes mechanical and chemical stresses on the nanovesicle surface and leads to the fast leakage of payloads [58, 59]. Protein corona also increases the rapid clearance of nanomedicines from blood circulation by macrophage uptake, and activates the immune systems [60, 61].

Biomacromolecules, such as ganglioside and PEG, preventing the opsonization process and limiting the activation of complement immune systems, can increase the physical stability of nanomedicines after systemic injection, and avoid the rapid leakage of payloads. In these attempts, we studied the stability of CDP-choline/Lip and CDP-choline/OX26Lip in PBS-HP by evaluating the average diameters of liposomes up to 24 h of incubation. A PBS solution (pH 7.4, 10 mM) was used as a control. The hydrodynamic diameters of CDP-choline/Lip and CDP-choline/OX26Lip were stable in PBS buffer up to 24 h of incubation (Fig. 4A).Fig. 4 Mean size variation of CDP-choline/Lip and CDP-choline/OX26Lip in PBS buffer (A) and PBS supplemented with human plasma (50% v/v) (B). The analysis was carried out at 37 ± 0.5 °C. Results are the average of three independent experiments ± standard deviation (S.D.). PBS buffer (10 mM, pH 7.4) was used as a control during the experiment. *p < 0.05, **p < 0.01 and ***p < 0.001 were considered statistically significant. The statistical analysis has been reported in the Table S1. Panel C is a schematic representation of the interaction between liposomes and plasma proteins during incubation time

Some variations of the CDP-choline/Lip and CDP-choline/OX26Lip for average sizes were obtained for nanovesicles incubated in PBS-HP (Fig. 4B). Namely, the average size of both nanomedicines slight decreased of ~10 nm after 2 h of incubation (Fig. 4B). The decrease of average sizes may depend on soft corona adsorbed on the liposomal surface, which caused a vesicle shrinkage due to the osmotic pressure generated on the external bilayer of the nanomedicines [62, 63]. The formation of a soft corona and the relative shrinkage of CDP-choline/Lip and CDP-choline/OX26Lip can further support the slight increase of CDP-choline release occurred after 2 h of incubation in PBS-HP (Fig. 3C).

By extending the incubation in PBS-HP up to 24 h, an increase in the CDP-choline/Lip and CDP-choline/OX26Lip mean size was obtained (Fig. 4B). This result can depend on the hard corona adsorbed on the surface of both nanomedicines. In fact, hard corona stuck the external bilayer of liposomes and changed their supramolecular structure [64, 65], thus leading to an increase of the nanomedicine hydrodynamic radius (Fig. 4B). The lack of nanomedicine aggregates, as evidenced by the absence of colloidal populations characterized by an average size equal to or greater than double the mean size of the nanomedicines before incubation, demonstrated that both CDP-choline/Lip and CDP-choline/OX26Lip were still stable following incubation in PBS-HP and no sedimentation occurred (Fig. 4B). This result was GM1- and PEG-dependent because both macromolecules shield the surface of both nanomedicines, thus hampering their aggregation after the interaction with circulating proteins [31].

Long term stability studies

Turbiscan Lab analysis, which provided a non-invasive measurement of long-term stability of liposomes, like other colloidal nanoparticles [40, 66], were used to endorse the physical stability of CDP-choline/Lip and CDP-choline/OX26Lip. Turbiscan analysis can predict the long-term stability of colloidal systems by correlating the variation of backscattering (ΔBS) and transmission (ΔT) to destabilization phenomena, i.e. aggregation, flocculation, creaming and sedimentation [67, 68].

The Turbiscan analysis was carried out both at 25 °C and 37 °C to simulate the room storage condition and body temperatures, respectively. ΔBS% and ΔT% was not over 5% for all tested samples (Fig. 5). These results demonstrated that CDP-choline/Lip and CDP-choline/OX26Lip are stable and there were no destabilization phenomena in agreement with previous published data [69].Fig. 5 Variation of backscattering and transmission profiles of CDP-choline/Lip and CDP-choline/OX26Lip. Panel A is a schematic representation of Turbiscan analysis. The analysis was carried out at 25 °C (panels B and D) and at 37 °C (panels C and E). Results are representative of three independent experiments and are reported as a function of time (0-60 min) and sample height (mm)

The absence of destabilization phenomena was further endorsed by the measurements of Turbiscan stability index (TSI), which corresponds to a TSI equal or below 6 for CDP-choline/Lip and CDP-choline/OX26Lip tested at 25 °C and 37 °C (Fig. 6). These results are in agreement with data previously published [34] and further highlighted the physical stability of CDP-choline/Lip and CDP-choline/OX26Lip according to ΔBS% and ΔT% data.Fig. 6 Turbiscan stability index (TSI) of CDP-choline/Lip and CDP-choline/OX26Lip. TSI was evaluated as a function of incubation time (0–1 h). The analysis was carried out at 25 ± 0.5 °C (A) and 37 ± 0.5 °C (B), and the results are representative of three independent experiments ± standard deviation (S.D.)

The colloidal stability of liposomes was also studied by analyzing their kinetic diameter profiles as a function of time for Turbiscan analysis. No significant variations were obtained during the incubation time, thus further endorsing the ΔBS%, ΔT% and TSI profiles as above reported (Fig. S1).

Pharmacokinetic profiles and RES organs uptake

The biodistribution of nanomedicines, after systemic administration, affects their long-circulation and metabolism, as well as clearance. Enzymes and circulating proteins modify the biodistribution and long-circulation of nanomedicine because they change interface properties and polymer coating by different mechanisms [70, 71].

CDP-choline/LipOX26 had a lower blood circulation time than CDP-choline/Lip, and the results were in agreement with data previously published by our research group [55], The blood circulation time was 30.0 ± 4.2% (CDP-choline/LipOX26) and 43.5 ± 5.3% (CDP-choline/Lip) of the administered dose at 12 h after systemic injection (Fig. 7A). The amount of CDP-choline/LipOX26 in the blood decreased up to 18.3 ± 1.9% at 24 h after systemic injection, while the amount of CDP-choline/Lip in the blood was still 31.3 ± 3.4% (Fig. 7A). The lower blood circulation time of the CDP-choline/LipOX26 than the CDP-choline/Lip, having a similar lipid composition, may depend on the high accumulation of OX26-conjugated liposomes in the spleen (Fig. 7B), due to the overexpression of transferrin receptor into the spleen and liver [72]. Although these results may look like a disadvantage of CDP-choline/LipOX26 compared to CDP-choline/Lip, the transferrin receptors in the brain endothelial vessels promote the transport of liposomes across the BBB and allow their accumulation into the brain [73, 74]. Moreover, targeted nanomedicines bind their specific receptors immediately after systemic in vivo administration and at early circulations (where no significant difference were found in the pharmacokinetic profiles of unconjugated-liposomes and OX26-conjugated liposomes), because there is a minimum adsorption of circulating proteins on the surface of nanomedicines and protein corona did not stick on their surface [75, 76]. Our hypothesis further agreed data previously published that widely discussed the use of OX26 antibody as targeting moiety to accumulate nanocarriers inside the brain by transferrin receptor mediated uptake [35, 73, 77].Fig. 7 Pharmacokinetic profiles (A) and RES organs (liver and spleen) uptake (B) of CDP-choline/LipOX26 and CDP-choline/Lip. Results are the average of three independent experiments ± standard deviation (S.D.). Statistically significant: *p < 0.05, **p < 0.01

In vivo therapeutic efficacy

The severity of brain damages, associated to ischemic event, depends on the timing of injected drug dosage between the stroke event and the brain reperfusion [78]. Indeed, the hypoxic conditions, related to ischemia, trigger several metabolic and electrolytic brain dysfunctions [79] as well as the release of various mediators, like the large production of reactive oxygen species (ROS), the lactate accumulation, the alteration of calcium homeostasis, the unbalance of potassium and sodium ions, the massive release of nitroxide. All these mediators supported the oxidative stress and provided the modification of macro environment [7, 80, 81], that caused the cell death during the ischemia [82–84]. In this attempt, a fast reperfusion of the tissues is needed to decrease the extension of the penumbra zona.

We previously demonstrated that CDP-choline/Lip, with a similar lipid composition, significantly decreased the damage associated to ischemic stroke in rodents and improved the recovery of brain performance after ischemia [19, 54]. Although the reduced pharmacokinetic profiles of OX26-conjugated liposomes, the targeting strategy improved the accumulation of payload in the brain tissue and increased the survival rate of ischemic and re-perfusion rats from 78% to 96% after 8 days (Fig. 8). This improvement depended on the specific accumulation of CDP-choline in the brain mediated by liposomes.Fig. 8 Survival rate of ischemic rat. The analysis was carried out after intravenous injection of CDP-choline/OX26Lip, CDP-choline/Lip or Saline solution 1 per day every day for 6 days (n = 15 for group). No significant variations of body weight were obtained for survived animals. Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/)

The efficacy of CDP-choline/OX26Lip was also studied by analyzing the lactate and lipid peroxidation levels 1 h after the liposome (at the dose of 20 mg/Kg) administration during the reperfusion process. The improved efficacy of CDP-choline/OX26Lip was further demonstrated by the analysis of lipid peroxidation rate (Table 2) that measures the degenerative event catalyzed by the accumulation of radical species in the hypoxic area during ischemia followed by reperfusion process. The lipid peroxidation was evaluated as a function of conjugated dienes, and the resulting data demonstrated that the use of CDP-choline/OX26Lip significantly decreased the peroxidation rate of almost 5-times compared to CDP-choline/Lip (3.1 ± 0.8 vs 13.9 ± 1.1 mmol/mg proteins, respectively). Whereas no significant variation was obtained in the lactate accumulation in the rat that have been treated with CDP-choline/OX26Lip compared to those treated with CDP-choline/Lip (Table 2). Table 2 Lactate and lipid peroxidation levels

Sample	Lactate
(nmol/mg proteins)	Diene peroxidation
(mmol/mg proteins)	
CDP-choline/Lip	12.3 ± 0.7	13.9 ± 1.1(###)	
CDP-choline/OX26Lip	10.8 ± 1.1	3.1 ± 0.8(###) (***)	
Saline	10.6 ± 0.7	40.7 ± 6.3	
The analysis was carried out 1 h after intravenous injection of CDP-choline/Lip, CDP-choline/OX26Lip or Saline solution after the re-perfusion of Wistar rats. Results are the average of five independent experiments ± standard deviation (S.D.)

Significance: ***p < 0.001 (CDP-choline/Lip vs CDP-choline/OX26Lip); ###p < 0.001 (liposomes vs saline)

The significant (***p < 0.001) decrease of lipid peroxidation rate demonstrated that the therapeutic efficacy of targeted CDP-choline/OX26Lip is higher than CDP-choline/Lip. These results demonstrated that CDP-choline/OX26Lip decreases the damage associated to the accumulation of ROS in the penumbra zone. This increase is higher than CDP-choline/Lip and caused a potentially reduction of post-ischemic neurodegeneration. CDP-choline/OX26Lip improved the accumulation of drug in the brain tissue and endorsed the higher targeting of CDP-choline/OX26Lip than CDP-choline/Lip.

These results clearly demonstrated that CDP-choline/OX26Lip increased the therapeutic efficacy of the entrapped drug in ischemic rat models than CDP-choline/Lip, and this nanomedicine may be used for the future treatment of cerebrovascular ischemic stroke.

Conclusion

In this study we demonstrated the improvement of CDP-choline therapeutic efficacy that has been delivered by using in OX26-conjugated liposomes with GM1 in the lipid components.

CDP-choline/OX26Lip had suitable physicochemical properties, were stable in human plasma and improved the therapeutic of CDP-choline in ischemic rat models compared to unconjugated CDP-choline/Lip. Namely, a massive reduction in the diene production was obtained when CDP-choline/OX26Lip was used (ca. 5-times less than CDP-choline/Lip). The improved efficacy of CDP-choline/OX26Lip depended on the specific binding of OX26 antibody with the transferrin receptor that is overexpressed in the BBB. This specific targeting increased the accumulation of liposomes inside the brain, promoted the brain uptake, and increased the survival rate of rats 8 days after the ischemic event (78% vs 96% for CDP-choline/Lip and CDP-choline/OX26Lip, respectively). These results highlighted the significant impact of OX26 antibody as targeting agents for the brain delivery and the liposomal transport across the BBB and may encourage a potential reassessment and use of CDP-choline with GM1 macromolecules for the therapy and rehabilitation of patients after of post-ischemic stroke.

Supplementary information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 382 kb)

Author contribution

Nicola d’Avanzo: data curation, formal analysis, investigation, writing of original draft, writing-review, and editing; Donatella Paolino: conceptualization, methodology, data curation, formal analysis, writing of original draft, writing- review and editing. Antonella Barone: data curation, investigation, and formal analysis. Anna Maria Tolomeo: data curation, formal analysis. Luigi Ciriolo, Antonia Mancuso, and Maria Chiara Cristiano: data curation, writing-review, and editing; Christian Celia, Xiaoyong Deng and Massimo Fresta: funding acquisition, conceptualization, and supervision. The first draft of the manuscript was written by Nicola d’Avanzo and Donatella Paolino; all authors read and approved the final manuscript.

Funding

Open access funding provided by Università degli studi "Magna Graecia" di Catanzaro within the CRUI-CARE Agreement. This work was supported by Ministero dell ‘Università e della Ricerca (MUR) [FAR 2018 (D56C18000780005), FAR 2019 (D54I19002790005)]; the European Union – NextGenerationEU, under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 - M4C2, Investment 1.5 – Call for tender No. 3277 of 30.12.2021, Italian Ministry of University, Award Number: ECS00000041, Project Title: “Innovation, digitalization and sustainability for the diffused economy in Central Italy”, Concession Degree No. 1057 of 23.06.2022 adopted by the Italian Ministry of University. CUP: D73C22000840006; Overseas Visiting Fellow Program 2022, University of Shanghai, China.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval

Approval was granted by the Bioethical Committee of the University Magna Graecia of Catanzaro, and the study was carried out in accordance with the protocol n. 235/2011, approved by the Italian Ministry of Health (National Directorate of Veterinary Services, Italy).

Consent to participate

This is not applicable to our current research.

Consent for publication

This is not applicable to our current research.

Competing interest

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Nicola d’Avanzo and Donatella Paolino equally contributed.
==== Refs
References

1. Feigin VL Stark BA Johnson CO Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the global burden of disease study 2019 Lancet Neurol 2021 20 795 820 10.1016/S1474-4422(21)00252-0 34487721
Feigin VL, Stark BA, Johnson CO, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2021;20:795–820. 10.1016/S1474-4422(21)00252-0.34487721 10.1016/S1474-4422(21)00252-0
2. Paul S Candelario-Jalil E Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies Exp Neurol 2021 335 113518 10.1016/j.expneurol.2020.113518 33144066
Paul S, Candelario-Jalil E. Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies. Exp Neurol. 2021;335:113518. 10.1016/j.expneurol.2020.113518.33144066 10.1016/j.expneurol.2020.113518
3. Ma VY Chan L Carruthers KJ Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain Arch Phys Med Rehabil 2014 95 986 995.e1 10.1016/j.apmr.2013.10.032 24462839
Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95:986–95.e1. 10.1016/j.apmr.2013.10.032.24462839 10.1016/j.apmr.2013.10.032
4. Flynn R MacWalter R Doney A The cost of cerebral ischaemia Neuropharmacology 2008 55 250 256 10.1016/j.neuropharm.2008.05.031 18573263
Flynn R, MacWalter R, Doney A. The cost of cerebral ischaemia. Neuropharmacology. 2008;55:250–6. 10.1016/j.neuropharm.2008.05.031.18573263 10.1016/j.neuropharm.2008.05.031
5. Rochmah TN Rahmawati IT Dahlui M Economic burden of stroke disease: a systematic review Int J Environ Res Public Health 2021 18 7552 10.3390/ijerph19074261 34299999
Rochmah TN, Rahmawati IT, Dahlui M, et al. Economic burden of stroke disease: A systematic review. Int J Environ Res Public Health. 2021;18:7552. 10.3390/ijerph19074261.34299999 10.3390/ijerph19074261
6. George MG Risk factors for ischemic stroke in younger adults: a focused update Stroke 2020 51 729 735 10.1161/strokeaha.119.024156 32078487
George MG. Risk factors for ischemic stroke in younger adults: A focused update. Stroke. 2020;51:729–35. 10.1161/strokeaha.119.024156.32078487 10.1161/strokeaha.119.024156
7. Tuo QZ Zhang ST Lei P Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications Med Res Rev 2022 42 259 305 10.1002/med.21817 33957000
Tuo QZ, Zhang ST, Lei P. Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications. Med Res Rev. 2022;42:259–305. 10.1002/med.21817.33957000 10.1002/med.21817
8. Nozohouri S Sifat AE Vaidya B Abbruscato TJ Novel approaches for the delivery of therapeutics in ischemic stroke Drug Discov Today 2020 25 535 10.1016/j.drudis.2020.01.007 31978522
Nozohouri S, Sifat AE, Vaidya B, Abbruscato TJ. Novel approaches for the delivery of therapeutics in ischemic stroke. Drug Discov Today. 2020;25:535. 10.1016/j.drudis.2020.01.007.31978522 10.1016/j.drudis.2020.01.007
9. Shi K Tian D-C Li Z-G Global brain inflammation in stroke Lancet Neurol 2019 18 1058 1066 10.1016/S1474-4422(19)30078-X 31296369
Shi K, Tian D-C, Li Z-G, et al. Global brain inflammation in stroke. Lancet Neurol. 2019;18:1058–66. 10.1016/S1474-4422(19)30078-X.31296369 10.1016/S1474-4422(19)30078-X
10. Kalogeris T Baines CP Krenz M Korthuis RJ Ischemia/reperfusion Compr Physiol 2016 7 113 10.1002/cphy.c160006 28135002
Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/reperfusion. Compr Physiol. 2016;7:113. 10.1002/cphy.c160006.28135002 10.1002/cphy.c160006
11. Sibani S Dipankar C Arijit B Cerebral ischemic stroke: cellular fate and therapeutic opportunities Front Biosci 2019 24 415 430 10.2741/4727
Sibani S, Dipankar C, Arijit B. Cerebral ischemic stroke: Cellular fate and therapeutic opportunities. Front Biosci. 2019;24:415–30. 10.2741/4727.10.2741/4727
12. Fisher M Savitz SI Pharmacological brain cytoprotection in acute ischaemic stroke—renewed hope in the reperfusion era Nat Rev Neurol 2022 18 193 202 10.1038/s41582-021-00605-6 35079135
Fisher M, Savitz SI. Pharmacological brain cytoprotection in acute ischaemic stroke—renewed hope in the reperfusion era. Nat Rev Neurol. 2022;18:193–202. 10.1038/s41582-021-00605-6.35079135 10.1038/s41582-021-00605-6
13. Overgaard K The effects of citicoline on acute ischemic stroke: a review J Stroke Cerebrovasc Dis 2014 23 1764 1769 10.1016/j.jstrokecerebrovasdis.2014.01.020 24739589
Overgaard K. The effects of citicoline on acute ischemic stroke: A review. J Stroke Cerebrovasc Dis. 2014;23:1764–9. 10.1016/j.jstrokecerebrovasdis.2014.01.020.24739589 10.1016/j.jstrokecerebrovasdis.2014.01.020
14. Alvarez-Sabín J Román GC Citicoline in vascular cognitive impairment and vascular dementia after stroke Stroke 2011 42 S40 S43 10.1161/STROKEAHA.110.606509 21164117
Alvarez-Sabín J, Román GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011;42:S40–3. 10.1161/STROKEAHA.110.606509.21164117 10.1161/STROKEAHA.110.606509
15. Dávalos A Alvarez-Sabín J Castillo J Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial) Lancet 2012 380 349 357 10.1016/S0140-6736(12)60813-7 22691567
Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380:349–57. 10.1016/S0140-6736(12)60813-7.22691567 10.1016/S0140-6736(12)60813-7
16. Clark WM Clark TD Treatment for acute stroke—the end of the citicoline saga Nat Rev Neurol 2012 8 484 485 10.1016/S0140-6736(12)60813-7 22868867
Clark WM, Clark TD. Treatment for acute stroke—the end of the citicoline saga. Nat Rev Neurol. 2012;8:484–5. 10.1016/S0140-6736(12)60813-7.22868867 10.1016/S0140-6736(12)60813-7
17. Adibhatla RM Citicoline in stroke and TBI clinical trials Nat Rev Neurol 2013 9 173 173 10.1038/nrneurol.2012.166-c1 23358483
Adibhatla RM. Citicoline in stroke and TBI clinical trials. Nat Rev Neurol. 2013;9:173–173. 10.1038/nrneurol.2012.166-c1.23358483 10.1038/nrneurol.2012.166-c1
18. Fresta M Wehrli E Puglisi G Enhanced therapeutic effect of cytidine-5′-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model Pharm Res 1995 12 1769 1774 10.1023/a:1016234226404 8592684
Fresta M, Wehrli E, Puglisi G. Enhanced therapeutic effect of cytidine-5′-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model. Pharm Res. 1995;12:1769–74. 10.1023/a:1016234226404.8592684 10.1023/a:1016234226404
19. Fresta M Puglisi G Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes1 Pharm Res 1999 16 1843 1849 10.1023/a:1018999225435 10644072
Fresta M, Puglisi G. Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes1. Pharm Res. 1999;16:1843–9. 10.1023/a:1018999225435.10644072 10.1023/a:1018999225435
20. Ghosh S Das N Mandal A Mannosylated liposomal cytidine 5′ diphosphocholine prevent age related global moderate cerebral ischemia reperfusion induced mitochondrial cytochrome c release in aged rat brain Neuroscience 2010 171 1287 1299 10.1016/j.neuroscience.2010.09.049 20883746
Ghosh S, Das N, Mandal A, et al. Mannosylated liposomal cytidine 5′ diphosphocholine prevent age related global moderate cerebral ischemia reperfusion induced mitochondrial cytochrome c release in aged rat brain. Neuroscience. 2010;171:1287–99. 10.1016/j.neuroscience.2010.09.049.20883746 10.1016/j.neuroscience.2010.09.049
21. Liu H Jablonska A Li Y Label-free CEST MRI detection of citicoline-liposome drug delivery in ischemic stroke Theranostics 2016 6 1588 10.7150/thno.15492 27446492
Liu H, Jablonska A, Li Y, et al. Label-free CEST MRI detection of citicoline-liposome drug delivery in ischemic stroke. Theranostics. 2016;6:1588. 10.7150/thno.15492.27446492 10.7150/thno.15492
22. Birolini G Valenza M Ottonelli I Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease J Control Release 2021 330 587 598 10.1016/j.jconrel.2020.12.051 33412229
Birolini G, Valenza M, Ottonelli I, et al. Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington’s disease. J Control Release. 2021;330:587–98. 10.1016/j.jconrel.2020.12.051.33412229 10.1016/j.jconrel.2020.12.051
23. Duskey JT Ottonelli I Da Ros F Novel peptide-conjugated nanomedicines for brain targeting: In vivo evidence Nanomedicine 2020 28 102226 10.1016/j.nano.2020.102226 32479916
Duskey JT, Ottonelli I, Da Ros F, et al. Novel peptide-conjugated nanomedicines for brain targeting: In vivo evidence. Nanomedicine. 2020;28:102226. 10.1016/j.nano.2020.102226.32479916 10.1016/j.nano.2020.102226
24. Tosi G Duskey J Kreuter J Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier Expert Opin Drug Deliv 2020 17 23 32 10.1080/17425247.2020.1698544 31774000
Tosi G, Duskey J, Kreuter J. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. Expert Opin Drug Deliv. 2020;17:23–32. 10.1080/17425247.2020.1698544.31774000 10.1080/17425247.2020.1698544
25. Gosk S Vermehren C Storm G Moos T Targeting anti—transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion J Cereb Blood Flow Metab 2004 24 1193 1204 10.1097/01.wcb.0000135592.28823.47 15545912
Gosk S, Vermehren C, Storm G, Moos T. Targeting anti—transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab. 2004;24:1193–204. 10.1097/01.wcb.0000135592.28823.47.15545912 10.1097/01.wcb.0000135592.28823.47
26. Mojarad-Jabali S Mahdinloo S Farshbaf M Transferrin receptor-mediated liposomal drug delivery: Recent trends in targeted therapy of cancer Expert Opin Drug Deliv 2022 19 6 685 705 10.1080/17425247.2022.2083106 35698794
Mojarad-Jabali S, Mahdinloo S, Farshbaf M, et al. Transferrin receptor-mediated liposomal drug delivery: Recent trends in targeted therapy of cancer. Expert Opin Drug Deliv. 2022;19(6):685–705. 10.1080/17425247.2022.2083106.35698794 10.1080/17425247.2022.2083106
27. Liu Z Zhang L He Q Effect of Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia–reperfusion in rats Int J Pharm 2015 489 131 138 10.1016/j.ijpharm.2015.04.049 25895718
Liu Z, Zhang L, He Q, et al. Effect of Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia–reperfusion in rats. Int J Pharm. 2015;489:131–8. 10.1016/j.ijpharm.2015.04.049.25895718 10.1016/j.ijpharm.2015.04.049
28. Benady A Freidin D Pick CG Rubovitch V GM1 ganglioside prevents axonal regeneration inhibition and cognitive deficits in a mouse model of traumatic brain injury Sci Rep 2018 8 13340 10.1038/s41598-018-31623-y 30190579
Benady A, Freidin D, Pick CG, Rubovitch V. GM1 ganglioside prevents axonal regeneration inhibition and cognitive deficits in a mouse model of traumatic brain injury. Sci Rep. 2018;8:13340. 10.1038/s41598-018-31623-y.30190579 10.1038/s41598-018-31623-y
29. Finsterwald C Dias S Magistretti PJ Lengacher S Ganglioside GM1 targets astrocytes to stimulate cerebral energy metabolism Front Pharmacol 2021 12 653842 10.3389/fphar.2021.653842 33995070
Finsterwald C, Dias S, Magistretti PJ, Lengacher S. Ganglioside GM1 targets astrocytes to stimulate cerebral energy metabolism. Front Pharmacol. 2021;12:653842. 10.3389/fphar.2021.653842.33995070 10.3389/fphar.2021.653842
30. d'Avanzo N Celia C Barone A Immunogenicity of polyethylene glycol based nanomedicines: Mechanisms, clinical implications and systematic approach Adv Ther 2020 3 1900170 10.1002/adtp.201900170
d’Avanzo N, Celia C, Barone A, et al. Immunogenicity of polyethylene glycol based nanomedicines: Mechanisms, clinical implications and systematic approach. Adv Ther. 2020;3:1900170. 10.1002/adtp.201900170.10.1002/adtp.201900170
31. d'Avanzo N Torrieri G Figueiredo P LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy Int J Pharm 2021 597 120346 10.1016/j.ijpharm.2021.120346 33545283
d’Avanzo N, Torrieri G, Figueiredo P, et al. LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy. Int J Pharm. 2021;597:120346. 10.1016/j.ijpharm.2021.120346.33545283 10.1016/j.ijpharm.2021.120346
32. Thomsen LB Linemann T Birkelund S Evaluation of targeted delivery to the brain using magnetic immunoliposomes and magnetic force Materials 2019 12 3576 10.3390/ma12213576 31683542
Thomsen LB, Linemann T, Birkelund S, et al. Evaluation of targeted delivery to the brain using magnetic immunoliposomes and magnetic force. Materials. 2019;12:3576. 10.3390/ma12213576.31683542 10.3390/ma12213576
33. Béduneau A Saulnier P Hindré F Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’fragments Biomaterials 2007 28 4978 4990 10.3390/ma12213576 17716725
Béduneau A, Saulnier P, Hindré F, et al. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’fragments. Biomaterials. 2007;28:4978–90. 10.3390/ma12213576.17716725 10.3390/ma12213576
34. Cristiano MC d’Avanzo N Mancuso A Ammonium glycyrrhizinate and Bergamot essential oil co-loaded ultradeformable nanocarriers: An effective natural nanomedicine for in vivo anti-inflammatory topical therapies Biomedicines 2022 10 1039 10.3390/biomedicines10051039 35625775
Cristiano MC, d’Avanzo N, Mancuso A, et al. Ammonium glycyrrhizinate and Bergamot essential oil co-loaded ultradeformable nanocarriers: An effective natural nanomedicine for in vivo anti-inflammatory topical therapies. Biomedicines. 2022;10:1039. 10.3390/biomedicines10051039.35625775 10.3390/biomedicines10051039
35. Monsalve Y Tosi G Ruozi B PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting Nanomedicine 2015 10 1735 1750 10.2217/nnm.15.29 26080696
Monsalve Y, Tosi G, Ruozi B, et al. PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. Nanomedicine. 2015;10:1735–50. 10.2217/nnm.15.29.26080696 10.2217/nnm.15.29
36. Palmosi T Tolomeo AM Cirillo C Small intestinal submucosa-derived extracellular matrix as a heterotopic scaffold for cardiovascular applications Front Bioeng Biotechnol 2022 10 1042434 10.3389/fbioe.2022.1042434 36578513
Palmosi T, Tolomeo AM, Cirillo C, et al. Small intestinal submucosa-derived extracellular matrix as a heterotopic scaffold for cardiovascular applications. Front Bioeng Biotechnol. 2022;10:1042434. 10.3389/fbioe.2022.1042434.36578513 10.3389/fbioe.2022.1042434
37. Lin J Song X Yin H Citicoline–liposome/polyurethane composite scaffolds regulate the inflammatory response of microglia to promote nerve regeneration J Mater Sci 2022 57 2073 2088 10.1007/s10853-021-06628-0
Lin J, Song X, Yin H, et al. Citicoline–liposome/polyurethane composite scaffolds regulate the inflammatory response of microglia to promote nerve regeneration. J Mater Sci. 2022;57:2073–88. 10.1007/s10853-021-06628-0.10.1007/s10853-021-06628-0
38. Xu H Ji H Li Z In vivo pharmacokinetics and in vitro release of imatinib mesylate-loaded liposomes for pulmonary delivery Int J Nanomedicine 2021 16 1221 10.2147/ijn.S294626 33628019
Xu H, Ji H, Li Z, et al. In vivo pharmacokinetics and in vitro release of imatinib mesylate-loaded liposomes for pulmonary delivery. Int J Nanomedicine. 2021;16:1221. 10.2147/ijn.S294626.33628019 10.2147/ijn.S294626
39. Almeida PV Shahbazi M-A Mäkilä E Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors Nanoscale 2014 6 10377 10387 10.1039/c4nr02187h 25074521
Almeida PV, Shahbazi M-A, Mäkilä E, et al. Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors. Nanoscale. 2014;6:10377–87. 10.1039/c4nr02187h.25074521 10.1039/c4nr02187h
40. Barone A Zimbo AM d’Avanzo N Thermoresponsive M1 macrophage-derived hybrid nanovesicles for improved in vivo tumor targeting Drug Deliv Transl Res 2023 13 3154 3168 10.1007/s13346-023-01378-9 37365403
Barone A, Zimbo AM, d’Avanzo N, et al. Thermoresponsive M1 macrophage-derived hybrid nanovesicles for improved in vivo tumor targeting. Drug Deliv Transl Res. 2023;13:3154–68. 10.1007/s13346-023-01378-9.37365403 10.1007/s13346-023-01378-9
41. Paolino D Cosco D Gaspari M Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes Biomaterials 2014 35 7101 7109 10.1016/j.biomaterials.2014.04.088 24836306
Paolino D, Cosco D, Gaspari M, et al. Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes. Biomaterials. 2014;35:7101–9. 10.1016/j.biomaterials.2014.04.088.24836306 10.1016/j.biomaterials.2014.04.088
42. Bhatia A Saikia PP Dkhar B Pyngrope H Anesthesia protocol for ear surgery in Wistar rats (animal research) Exp Anim 2022 5 183 188 10.1002/ame2.12198
Bhatia A, Saikia PP, Dkhar B, Pyngrope H. Anesthesia protocol for ear surgery in Wistar rats (animal research). Exp Anim. 2022;5:183–8. 10.1002/ame2.12198.10.1002/ame2.12198
43. Zhao Z Ukidve A Krishnan V Mitragotri S Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers Adv Drug Deliv Rev 2019 143 3 21 10.1016/j.addr.2019.01.002 30639257
Zhao Z, Ukidve A, Krishnan V, Mitragotri S. Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers. Adv Drug Deliv Rev. 2019;143:3–21. 10.1016/j.addr.2019.01.002.30639257 10.1016/j.addr.2019.01.002
44. Galleguillos D Wang Q Steinberg N Anti-inflammatory role of GM1 and other gangliosides on microglia J Neuroinflammation 2022 19 9 10.1186/s12974-021-02374-x 34991625
Galleguillos D, Wang Q, Steinberg N, et al. Anti-inflammatory role of GM1 and other gangliosides on microglia. J Neuroinflammation. 2022;19:9. 10.1186/s12974-021-02374-x.34991625 10.1186/s12974-021-02374-x
45. Gong G Yin L Yuan L Ganglioside GM1 protects against high altitude cerebral edema in rats by suppressing the oxidative stress and inflammatory response via the PI3K/AKT-Nrf2 pathway Mol Immunol 2018 95 91 98 10.1016/j.molimm.2018.02.001 29428576
Gong G, Yin L, Yuan L, et al. Ganglioside GM1 protects against high altitude cerebral edema in rats by suppressing the oxidative stress and inflammatory response via the PI3K/AKT-Nrf2 pathway. Mol Immunol. 2018;95:91–8. 10.1016/j.molimm.2018.02.001.29428576 10.1016/j.molimm.2018.02.001
46. d’Avanzo N Sidorenko V Simón-Gracia L C-end rule peptide-guided niosomes for prostate cancer cell targeting J Drug Deliv Sci Technol 2023 91 105162 10.1016/j.jddst.2023.105162
d’Avanzo N, Sidorenko V, Simón-Gracia L, et al. C-end rule peptide-guided niosomes for prostate cancer cell targeting. J Drug Deliv Sci Technol. 2023;91:105162. 10.1016/j.jddst.2023.105162.10.1016/j.jddst.2023.105162
47. Hamadou AH Zhang J Chen C Vitamin C and β-carotene co-loaded in marine and egg nanoliposomes J Food Eng 2023 340 111315 10.1016/j.jfoodeng.2022.111315
Hamadou AH, Zhang J, Chen C, et al. Vitamin C and β-carotene co-loaded in marine and egg nanoliposomes. J Food Eng. 2023;340:111315. 10.1016/j.jfoodeng.2022.111315.10.1016/j.jfoodeng.2022.111315
48. Al-Ahmady ZS Jasim D Ahmad SS Selective liposomal transport through blood brain barrier disruption in ischemic stroke reveals two distinct therapeutic opportunities ACS Nano 2019 13 12470 12486 10.1021/acsnano.9b01808 31693858
Al-Ahmady ZS, Jasim D, Ahmad SS, et al. Selective liposomal transport through blood brain barrier disruption in ischemic stroke reveals two distinct therapeutic opportunities. ACS Nano. 2019;13:12470–86. 10.1021/acsnano.9b01808.31693858 10.1021/acsnano.9b01808
49. Mokdad R Seguin C Fournel S Anti-inflammatory effects of free and liposome-encapsulated Algerian thermal waters in RAW 264.7 macrophages Int J Pharm 2022 614 121452 10.1016/j.ijpharm.2022.121452 35007687
Mokdad R, Seguin C, Fournel S, et al. Anti-inflammatory effects of free and liposome-encapsulated Algerian thermal waters in RAW 264.7 macrophages. Int J Pharm. 2022;614:121452. 10.1016/j.ijpharm.2022.121452.35007687 10.1016/j.ijpharm.2022.121452
50. Li J Chang C Zhai J Ascorbyl palmitate effects on the stability of curcumin-loaded soybean phosphatidylcholine liposomes Food Biosci 2021 41 100923 10.1016/j.fbio.2021.100923
Li J, Chang C, Zhai J, et al. Ascorbyl palmitate effects on the stability of curcumin-loaded soybean phosphatidylcholine liposomes. Food Biosci. 2021;41:100923. 10.1016/j.fbio.2021.100923.10.1016/j.fbio.2021.100923
51. Vakili-Ghartavol R Rezayat SM Faridi-Majidi R Optimization of docetaxel loading conditions in liposomes: Proposing potential products for metastatic breast carcinoma chemotherapy Sci Rep 2020 10 5569 10.1038/s41598-020-62501-1 32221371
Vakili-Ghartavol R, Rezayat SM, Faridi-Majidi R, et al. Optimization of docetaxel loading conditions in liposomes: Proposing potential products for metastatic breast carcinoma chemotherapy. Sci Rep. 2020;10:5569. 10.1038/s41598-020-62501-1.32221371 10.1038/s41598-020-62501-1
52. Saraiva C Praça C Ferreira R Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases J Control Release 2016 235 34 47 10.1016/j.jconrel.2016.05.044 27208862
Saraiva C, Praça C, Ferreira R, et al. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34–47. 10.1016/j.jconrel.2016.05.044.27208862 10.1016/j.jconrel.2016.05.044
53. Pereira S Egbu R Jannati G Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity Int J Pharm 2016 514 150 159 10.1016/j.ijpharm.2016.06.057 27863659
Pereira S, Egbu R, Jannati G. Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity. Int J Pharm. 2016;514:150–9. 10.1016/j.ijpharm.2016.06.057.27863659 10.1016/j.ijpharm.2016.06.057
54. Fresta M Puglisi G Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5I-diphosphate choline Life Sci 1997 61 1227 1235 10.1016/s0024-3205(97)00667-x 9324064
Fresta M, Puglisi G. Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5I-diphosphate choline. Life Sci. 1997;61:1227–35. 10.1016/s0024-3205(97)00667-x.9324064 10.1016/s0024-3205(97)00667-x
55. Fresta M Puglisi G Biological effects of CDP-choline loaded long circulating liposomes on rat cerebral post-ischemic reperfusion Int J Pharm 1996 134 89 97 10.1016/0378-5173(95)04448-5
Fresta M, Puglisi G. Biological effects of CDP-choline loaded long circulating liposomes on rat cerebral post-ischemic reperfusion. Int J Pharm. 1996;134:89–97. 10.1016/0378-5173(95)04448-5.10.1016/0378-5173(95)04448-5
56. Lee H Larson RG Adsorption of plasma proteins onto PEGylated lipid bilayers: The effect of PEG size and grafting density Biomacromolecules 2016 17 1757 1765 10.1021/acs.biomac.6b00146 27046506
Lee H, Larson RG. Adsorption of plasma proteins onto PEGylated lipid bilayers: The effect of PEG size and grafting density. Biomacromolecules. 2016;17:1757–65. 10.1021/acs.biomac.6b00146.27046506 10.1021/acs.biomac.6b00146
57. Jyothi VGS Bulusu R Rao BVK Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: An update Int J Pharm 2022 624 122022 10.1016/j.ijpharm.2022.122022 35843364
Jyothi VGS, Bulusu R, Rao BVK, et al. Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: An update. Int J Pharm. 2022;624:122022. 10.1016/j.ijpharm.2022.122022.35843364 10.1016/j.ijpharm.2022.122022
58. Al-Ahmady ZS Hadjidemetriou M Gubbins J Kostarelos K Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes J Control Release 2018 276 157 167 10.1016/j.jconrel.2018.02.038 29522832
Al-Ahmady ZS, Hadjidemetriou M, Gubbins J, Kostarelos K. Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes. J Control Release. 2018;276:157–67. 10.1016/j.jconrel.2018.02.038.29522832 10.1016/j.jconrel.2018.02.038
59. Hadjidemetriou M Al-Ahmady Z Kostarelos K Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles Nanoscale 2016 8 6948 6957 10.1039/c5nr09158f 26961355
Hadjidemetriou M, Al-Ahmady Z, Kostarelos K. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale. 2016;8:6948–57. 10.1039/c5nr09158f.26961355 10.1039/c5nr09158f
60. Rampado R Crotti S Caliceti P Recent advances in understanding the protein corona of nanoparticles and in the formulation of “stealthy” nanomaterials Front Bioeng Biotechnol 2020 8 166 10.3389/fbioe.2020.00166 32309278
Rampado R, Crotti S, Caliceti P, et al. Recent advances in understanding the protein corona of nanoparticles and in the formulation of “stealthy” nanomaterials. Front Bioeng Biotechnol. 2020;8:166. 10.3389/fbioe.2020.00166.32309278 10.3389/fbioe.2020.00166
61. Xiao W Gao H The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system Int J Pharm 2018 552 328 339 10.1016/j.ijpharm.2018.10.011 30308270
Xiao W, Gao H. The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system. Int J Pharm. 2018;552:328–39. 10.1016/j.ijpharm.2018.10.011.30308270 10.1016/j.ijpharm.2018.10.011
62. Wolfram J Suri K Yang Y Shrinkage of pegylated and non-pegylated liposomes in serum Colloids Surf B 2014 114 294 300 10.1016/j.colsurfb.2013.10.009
Wolfram J, Suri K, Yang Y, et al. Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf B. 2014;114:294–300. 10.1016/j.colsurfb.2013.10.009.10.1016/j.colsurfb.2013.10.009
63. Kari OK Ndika J Parkkila P In situ analysis of liposome hard and soft protein corona structure and composition in a single label-free workflow Nanoscale 2020 12 1728 1741 10.1039/c9nr08186k 31894806
Kari OK, Ndika J, Parkkila P, et al. In situ analysis of liposome hard and soft protein corona structure and composition in a single label-free workflow. Nanoscale. 2020;12:1728–41. 10.1039/c9nr08186k.31894806 10.1039/c9nr08186k
64. García-Álvarez R Hadjidemetriou M Sánchez-Iglesias A In vivo formation of protein corona on gold nanoparticles. The effect of their size and shape Nanoscale 2018 10 1256 1264 10.1039/c7nr08322j 29292433
García-Álvarez R, Hadjidemetriou M, Sánchez-Iglesias A, et al. In vivo formation of protein corona on gold nanoparticles. The effect of their size and shape. Nanoscale. 2018;10:1256–64. 10.1039/c7nr08322j.29292433 10.1039/c7nr08322j
65. Hadjidemetriou M McAdam S Garner G The human in vivo biomolecule corona onto PEGylated liposomes: A proof-of-concept clinical study Adv Mater 2019 31 1803335 10.1002/adma.201803335
Hadjidemetriou M, McAdam S, Garner G, et al. The human in vivo biomolecule corona onto PEGylated liposomes: A proof-of-concept clinical study. Adv Mater. 2019;31:1803335. 10.1002/adma.201803335.10.1002/adma.201803335
66. Mengual O Meunier G Cayré I TURBISCAN MA 2000: Multiple light scattering measurement for concentrated emulsion and suspension instability analysis Talanta 1999 50 445 456 10.1016/s0039-9140(99)00129-0 18967735
Mengual O, Meunier G, Cayré I, et al. TURBISCAN MA 2000: Multiple light scattering measurement for concentrated emulsion and suspension instability analysis. Talanta. 1999;50:445–56. 10.1016/s0039-9140(99)00129-0.18967735 10.1016/s0039-9140(99)00129-0
67. Pereira GG Detoni CB Balducci AG Hyaluronate nanoparticles included in polymer films for the prolonged release of vitamin E for the management of skin wounds Eur J Pharm Sci 2016 83 203 211 10.1016/j.ejps.2016.01.002 26769495
Pereira GG, Detoni CB, Balducci AG, et al. Hyaluronate nanoparticles included in polymer films for the prolonged release of vitamin E for the management of skin wounds. Eur J Pharm Sci. 2016;83:203–11. 10.1016/j.ejps.2016.01.002.26769495 10.1016/j.ejps.2016.01.002
68. Derbali RM Aoun V Moussa G Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: A comparative study Mol Pharm 2019 16 1906 1916 10.1021/acs.molpharmaceut.8b01256 30900903
Derbali RM, Aoun V, Moussa G, et al. Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: A comparative study. Mol Pharm. 2019;16:1906–16. 10.1021/acs.molpharmaceut.8b01256.30900903 10.1021/acs.molpharmaceut.8b01256
69. d'Avanzo N Cristiano MC Di Marzio L Multidrug idebenone/naproxen co-loaded aspasomes for significant in vivo anti-inflammatory activity ChemMedChem 2022 17 e202200067 10.1002/cmdc.202200067 35194952
d’Avanzo N, Cristiano MC, Di Marzio L, et al. Multidrug idebenone/naproxen co-loaded aspasomes for significant in vivo anti-inflammatory activity. ChemMedChem. 2022;17:e202200067. 10.1002/cmdc.202200067.35194952 10.1002/cmdc.202200067
70. Bourquin J Milosevic A Hauser D Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials Adv Mater 2018 30 1704307 10.1002/adma.201704307
Bourquin J, Milosevic A, Hauser D, et al. Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials. Adv Mater. 2018;30:1704307. 10.1002/adma.201704307.10.1002/adma.201704307
71. Imperlini E Celia C Cevenini A Nano-bio interface between human plasma and niosomes with different formulations indicates protein corona patterns for nanoparticle cell targeting and uptake Nanoscale 2021 13 5251 5269 10.1039/d0nr07229j 33666624
Imperlini E, Celia C, Cevenini A, et al. Nano-bio interface between human plasma and niosomes with different formulations indicates protein corona patterns for nanoparticle cell targeting and uptake. Nanoscale. 2021;13:5251–69. 10.1039/d0nr07229j.33666624 10.1039/d0nr07229j
72. Yu Y Jiang L Wang H Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis Blood 2020 136 726 739 10.1182/blood.2019002907 32374849
Yu Y, Jiang L, Wang H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. Blood. 2020;136:726–39. 10.1182/blood.2019002907.32374849 10.1182/blood.2019002907
73. Wu Y Song X Kebebe D Brain targeting of Baicalin and Salvianolic acid B combination by OX26 functionalized nanostructured lipid carriers Int J Pharm 2019 571 118754 10.1016/j.ijpharm.2019.118754 31604118
Wu Y, Song X, Kebebe D, et al. Brain targeting of Baicalin and Salvianolic acid B combination by OX26 functionalized nanostructured lipid carriers. Int J Pharm. 2019;571:118754. 10.1016/j.ijpharm.2019.118754.31604118 10.1016/j.ijpharm.2019.118754
74. Liu Z Zhao H Shu L Preparation and evaluation of Baicalin-loaded cationic solid lipid nanoparticles conjugated with OX26 for improved delivery across the BBB Drug Dev Ind Pharm 2015 41 353 361 10.3109/03639045.2013.861478 25784073
Liu Z, Zhao H, Shu L, et al. Preparation and evaluation of Baicalin-loaded cationic solid lipid nanoparticles conjugated with OX26 for improved delivery across the BBB. Drug Dev Ind Pharm. 2015;41:353–61. 10.3109/03639045.2013.861478.25784073 10.3109/03639045.2013.861478
75. Zhang Y Zhang L Cai C In situ study of structural changes: Exploring the mechanism of protein corona transition from soft to hard J. Colloid Interface Sci 2024 654 935 944 10.1016/j.jcis.2023.10.095 37898077
Zhang Y, Zhang L, Cai C, et al. In situ study of structural changes: Exploring the mechanism of protein corona transition from soft to hard. J Colloid Interface Sci. 2024;654:935–44. 10.1016/j.jcis.2023.10.095.37898077 10.1016/j.jcis.2023.10.095
76. Dolci M Wang Y Nooteboom SW Real-time optical tracking of protein corona formation on single nanoparticles in serum ACS Nano 2023 17 20167 20178 10.1021/acsnano.3c05872 37802067
Dolci M, Wang Y, Nooteboom SW, et al. Real-time optical tracking of protein corona formation on single nanoparticles in serum. ACS Nano. 2023;17:20167–78. 10.1021/acsnano.3c05872.37802067 10.1021/acsnano.3c05872
77. Yue P-J He L Qiu S-W OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma Mol Cancer 2014 13 1 13 10.1186/1476-4598-13-191 24387052
Yue P-J, He L, Qiu S-W, et al. OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma. Mol Cancer. 2014;13:1–13. 10.1186/1476-4598-13-191.24387052 10.1186/1476-4598-13-191
78. Kuriakose D Xiao Z Pathophysiology and treatment of stroke: Present status and future perspectives Int J Mol Sci 2020 10.3390/ijms21207609 33076218
Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: Present status and future perspectives. Int J Mol Sci. 2020. 10.3390/ijms21207609.33076218 10.3390/ijms21207609
79. Sarkar S Chakraborty D Bhowmik A Ghosh MK Cerebral ischemic stroke: Cellular fate and therapeutic opportunities Front Biosci (Landmark Ed) 2019 24 435 450 10.2741/4727 30468665
Sarkar S, Chakraborty D, Bhowmik A, Ghosh MK. Cerebral ischemic stroke: Cellular fate and therapeutic opportunities. Front Biosci (Landmark Ed). 2019;24:435–50. 10.2741/4727.30468665 10.2741/4727
80. Bano D Nicotera P Ca2+ signals and neuronal death in brain ischemia Stroke 2007 38 674 676 10.1161/01.STR.0000256294.46009.29 17261713
Bano D, Nicotera P. Ca2+ signals and neuronal death in brain ischemia. Stroke. 2007;38:674–6. 10.1161/01.STR.0000256294.46009.29.17261713 10.1161/01.STR.0000256294.46009.29
81. Yamagata K Lactate supply from astrocytes to neurons and its role in ischemic stroke-induced neurodegeneration Neuroscience 2022 481 219 231 10.1016/j.neuroscience.2021.11.035 34843897
Yamagata K. Lactate supply from astrocytes to neurons and its role in ischemic stroke-induced neurodegeneration. Neuroscience. 2022;481:219–31. 10.1016/j.neuroscience.2021.11.035.34843897 10.1016/j.neuroscience.2021.11.035
82. Liu Y Wang X Li X A co-doped Fe(3)O(4) nanozyme shows enhanced reactive oxygen and nitrogen species scavenging activity and ameliorates the deleterious effects of ischemic stroke ACS Appl Mater Interfaces 2021 13 46213 46224 10.1021/acsami.1c06449 34546708
Liu Y, Wang X, Li X, et al. A co-doped Fe(3)O(4) nanozyme shows enhanced reactive oxygen and nitrogen species scavenging activity and ameliorates the deleterious effects of ischemic stroke. ACS Appl Mater Interfaces. 2021;13:46213–24. 10.1021/acsami.1c06449.34546708 10.1021/acsami.1c06449
83. Cui Y Zhang Y Zhao X ACSL4 exacerbates ischemic stroke by promoting ferroptosis-induced brain injury and neuroinflammation Brain Behav Immun 2021 93 312 321 10.1016/j.bbi.2021.01.003 33444733
Cui Y, Zhang Y, Zhao X, et al. ACSL4 exacerbates ischemic stroke by promoting ferroptosis-induced brain injury and neuroinflammation. Brain Behav Immun. 2021;93:312–21. 10.1016/j.bbi.2021.01.003.33444733 10.1016/j.bbi.2021.01.003
84. Li P Stetler RA Leak RK Oxidative stress and DNA damage after cerebral ischemia: Potential therapeutic targets to repair the genome and improve stroke recovery Neuropharmacology 2018 134 208 217 10.1016/j.neuropharm.2017.11.011 29128308
Li P, Stetler RA, Leak RK, et al. Oxidative stress and DNA damage after cerebral ischemia: Potential therapeutic targets to repair the genome and improve stroke recovery. Neuropharmacology. 2018;134:208–17. 10.1016/j.neuropharm.2017.11.011.29128308 10.1016/j.neuropharm.2017.11.011
